J&J is lagging behind its competitors, as its efficacy rates were proven to be lower than that of Pfizer and Moderna.
A pack and vials of the single-dose Johnson & Johnson Janssen Covid-19 vaccine photographed on April 30, 2021, at the ZNA Middelheim hospital in Antwerp | AFP